Literature DB >> 32392555

The Pathology of Amyloidosis in Classification: A Review.

Maria M Picken1.   

Abstract

BACKGROUND: The amyloidoses are a rare and heterogeneous group of disorders that are characterized by the deposition of abnormally folded proteins in tissues ultimately leading to organ damage. The deposits are mainly extracellular and are recognizable by their affinity for Congo red and their yellow-green birefringence under polarized light. Current classification of amyloid in medical practice is based on the amyloid protein type. To date, 36 proteins have been identified as being amyloidogenic in humans.
SUMMARY: in clinical practice, it is critical to distinguish between treatable versus non-treatable amyloidoses. Moreover, amyloidoses with a genetic component must be distinguished from the sporadic types and systemic amyloidoses must be distinguished from the localized forms. Among the systemic amyloidoses, AL continues to be the most common amyloid diagnosis in the developed world; other clinically significant types include AA, ALECT2, and ATTR. The latter is emerging as an underdiagnosed type in both the hereditary and wild-type setting. Other hereditary amyloidoses include AFib, several amyloidoses derived from apolipoproteins, AGel, ALys, etc. In a dialysis setting, systemic amyloid derived from β2 microglobulin (Aβ2M) should be considered, although a very rare hereditary variant has also been reported; several amyloidoses may be typically associated with aging and several iatrogenic types have also emerged. Determination of the amyloid protein type is imperative before specific therapy can be implemented and the current methods are briefly summarized. A brief overview of the target organ involvement by amyloid type is also included. Key Messages: (1) Early diagnosis of amyloidosis continues to pose a significant challenge and requires the participation of many clinical and laboratory specialties. (2) Determination of the protein type is imperative before specific therapy can be implemented. (3) While mass spectrometry has emerged as the preferred method of amyloid typing, careful application of immune methods is still clinically useful but caution and experience, as well as awareness of the limitations of each method, are necessary in their interpretation. (4) While the spectrum of amyloidoses continues to expand, it is critical to distinguish between those that are currently treatable versus those that are untreatable and avoid causing harm by inappropriate treatment.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Amyloidosis; Hereditary; Organ system; Pathology

Year:  2020        PMID: 32392555     DOI: 10.1159/000506696

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  19 in total

1.  Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint.

Authors:  Saeed Ali Alshehri; Mahmoud Rezk Abdelwahed Hussein
Journal:  Gastroenterology Res       Date:  2020-08-14

2.  Discrete binding patterns of two heparin-reactive proteins, basic fibroblast growth factor and peptide p5R, in amyloid-laden and healthy mice.

Authors:  Emily B Martin; Robert Donnell; Tina Richey; Alan Stuckey; Stephen J Kennel; Jonathan S Wall
Journal:  Biochem Biophys Res Commun       Date:  2021-03-19       Impact factor: 3.575

3.  The Heart of the Alzheimer's: A Mindful View of Heart Disease.

Authors:  Alessandro Evangelisti; Helen Butler; Federica Del Monte
Journal:  Front Physiol       Date:  2021-01-27       Impact factor: 4.566

4.  A Pilot Study of Rare Renal Amyloidosis Based on FFPE Proteomics.

Authors:  Shuang Meng; Wenwen Xia; Li Xia; Li Zhou; Jing Xu; Xiaoxia Pan; Liyuan Meng
Journal:  Molecules       Date:  2021-11-29       Impact factor: 4.411

5.  An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma.

Authors:  Shamis Khan; Sarah Premji; Quillan Huang; Gordana Verstovsek; Sita Bushan; Sarvari Venkata Yellapragada
Journal:  Clin Case Rep       Date:  2021-12-09

6.  Angiographic dark choroid in systemic non-hereditary amyloidosis.

Authors:  Konstantin V Astafurov; Andrew J Barkmeier
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-08

7.  Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis.

Authors:  Hiroki Yamaguchi; Hironori Kawahara; Noriyuki Kodera; Ayanori Kumaki; Yasutake Tada; Zixin Tang; Kenji Sakai; Kenjiro Ono; Masahito Yamada; Rikinari Hanayama
Journal:  Front Mol Biosci       Date:  2022-03-23

8.  The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis.

Authors:  Niki Lama; Alexandros Briasoulis; Efstratios Karavasilis; Kimon Stamatelopoulos; Angeliki Chasouraki; Efthymia Alexopoulou; Stavros Spiliopoulos; Foteini Theodorakakou; Meletios Athanasios Dimopoulos; Efstathios Kastritis; Nikolaos L Kelekis
Journal:  Insights Imaging       Date:  2022-03-26

Review 9.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11

Review 10.  Inherited Neuromuscular Disorders: Which Role for Serum Biomarkers?

Authors:  Antonino Lupica; Vincenzo Di Stefano; Andrea Gagliardo; Salvatore Iacono; Antonia Pignolo; Salvatore Ferlisi; Angelo Torrente; Sonia Pagano; Massimo Gangitano; Filippo Brighina
Journal:  Brain Sci       Date:  2021-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.